Q-omics provides the consensus-scored GRAMD2A profile across patient tissues and cancer cell-line models. GRAMD2A expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, GRAMD2A is differentially expressed in 15, with the highest sampling consensus in THCA. Additionally, GRAMD2A RNA expression shows 18,077 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, THCA, and THYM as cancer lineages where GRAMD2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRAMD2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRAMD2A survival associations across molecular data types. GRAMD2A RNA expression shows survival associations in the most cancer types (17), followed by mutation status (7) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRAMD2A RNA expression–survival associations across cancer types. High GRAMD2A expression shows unfavorable associations in LGG, MESO, TGCT and DLBC, but favorable associations in KIRP and LUAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for GRAMD2A RNA expression.
This table summarizes GRAMD2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GRAMD2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRAMD2A shows lower tumor expression in THCA, KIRC, KICH, LUAD and LUSC and higher tumor expression in COAD. The THCA box plot shows higher GRAMD2A RNA expression in normal versus tumor tissue (log2 FC = −2.377, t-test p < 0.001).
This table shows molecular features associated with GRAMD2A in patient tissues and cancer cell lines. In patient samples, GRAMD2A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, GRAMD2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_SCLC.
